Microvascular Therapeutics announces Founder and Chief Executive Officer (CEO) Dr. Evan Unger as panelist in Commercializing SBIR/STTR Technologies Discussion at 2025 BIO International Convention

Boston, MA – June 18, 2025 – Microvascular Therapeutics (MVT) is pleased to announce Founder and CEO, Dr. Evan Unger, as speaker on the National Institutes of Health (NIH) Panel Commercializing SBIR/STTR Technologies at the 2025 BIO International Convention on June 18th in Boston, MA, Room 210A, 2:30 pm EST, Boston Convention Center. As a founder of four biotech companies and inventor on 127 issued US patents, Dr. Unger will discuss his experience with the application of non-dilutive funding as a catalyst to innovation in the biopharmaceutical and life sciences industry.  Dr. Unger has received multiple NIH SBIR *Small Business Innovation           Research) grants, including Phase I, Phase II, Phase IIb grants as well as awards from the Department of Defense (DOD) and the Biomedical Advanced Research and Development Authority (BARDA). Non-dilutive funding has helped Dr. Unger to develop three FDA-approved drugs as well as current on-going clinical programs of several novel agents.

About Microvascular Therapeutics:

MVT is a privately held clinical-stage biopharmaceutical company based in Utah, developing the next generation of ultrasound contrast agents and theranostic products for use with biomedical ultrasound. Dr. Unger previously developed the world’s #1 selling ultrasound contrast agent, Perflutren. MVT’s new, patented ultrasound contrast agent, CardiSon, recently finished a Phase II clinical trial showing outstanding performance and safety. CardiSon is slated for room temperature storage and ease of use. Based upon CardiSon, MVT has developed condensed phase nanobubbles for theranostics. The patented nanobubble technology is in advanced preclinical development for the treatment of vascular diseases and cancer, funded by NIH and DOD.

“We have been fortunate to have obtained support from the National Cancer (NCI), National Heart, Blood and Lung (NHLBI), National institute of Aging (NIA) and other NIH institutes for the technology we are developing at MVT.  The non-dilutive funds represent an essential step for the advancement of innovative products, often discovered in academia and transferred to a startup company”.  Says Emmanuelle Meuillet, Ph. D., Chief Operating and Scientific Offer at MVT.  She adds “Our lead product, MVT-100 (CardiSon) was tested in the clinic thanks to a Phase II SBIR from the NHLBI”.  The NIH truly accompany companies like MVT throughout their drug/device development journey.    

   Forward-looking statement

This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to pursue our regulatory strategy, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees. These risks should not be construed as exhaustive. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.